CVSHealthcare · Healthcare PlansThe 27 Wall Street analysts covering CVS Health Corp. hold a median 12-month price target of $113 — +25.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores CVS Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (93): The share price has been relatively steady.
Quality (23): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CVS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +25.0% from it.
Of the 20 most recent actions, 8 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | Leerink Partners | Maintains | Outperform | $119 → $112 |
| 3 Sept 2026 | UBS | Maintains | Buy | $126 → $118 |
| 19 Aug 2026 | Argus Research | Maintains | Buy | $104 → $114 |
| 19 Aug 2026 | Argus Research | Maintains | Buy | — |
| 12 Aug 2026 | JP Morgan | Maintains | Overweight | $111 → $118 |
| 12 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 6 Aug 2026 | Barclays | Maintains | Overweight | — |
| 6 Aug 2026 | Barclays | Maintains | Overweight | $106 → $108 |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $130 → $125 |
| 6 Aug 2026 | UBS | Maintains | Buy | — |
| 6 Aug 2026 | UBS | Maintains | Buy | $122 → $126 |
| 25 July 2026 | UBS | Maintains | Buy | — |
| 24 July 2026 | UBS | Maintains | Buy | $115 → $122 |
| 14 July 2026 | Truist Securities | Maintains | Buy | — |
| 14 July 2026 | Truist Securities | Maintains | Buy | $108 → $118 |
| 13 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 13 July 2026 | Wells Fargo | Maintains | Overweight | $103 → $123 |
| 9 July 2026 | RBC Capital | Maintains | Outperform | — |
| 9 July 2026 | RBC Capital | Maintains | Outperform | $107 → $113 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, CVS Health Corp. returned +17.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 33% of US stocks
Cheaper than 89% of US stocks
Cheaper than 56% of US stocks
Cheaper than 36% of US stocks
Higher than 44% of US stocks
Higher than 90% of US stocks
Higher than 14% of US stocks
Higher than 52% of US stocks
Higher than 50% of US stocks
Higher than 55% of US stocks
Higher than 65% of US stocks
Higher than 86% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CVS Health Corp. has a market value of $112.0B and an enterprise value of $174.8B.
Revenue in the twelve months to 30 June 2026: $415.1B. The latest quarter grew 7.1% year on year.
Net income over the same four quarters: $4.9B, a 1.2% net margin.
Diluted earnings per share, trailing twelve months: $3.78.
Free cash flow in the twelve months to 30 June 2026: $11.8B.
CVS Health Corp. spent $3.4B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 23.0×; forward P/E: 10.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 3.04%, paying out 70% of earnings.
CVS Health Corp. employs 219,000 people — $1.9M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CVS Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research compares CVS Health with Alignment Healthcare, saying CVS has stronger returns, rising earnings estimates and a lower valuation. It also says Aetna’s turnaround is gaining traction.
Why it matters — The comparison highlights returns, earnings estimates, valuation and Aetna’s progress as factors relevant to monitoring CVS.
CVS Pharmacy Inc. and subsidiaries agreed to pay $315 million to resolve a Justice Department case alleging they unlawfully dispensed medically unnecessary prescriptions for highly addictive opioids.
Why it matters — The settlement and allegations are relevant to CVS watchers assessing the company's legal and regulatory exposure.
MinuteClinic earned its seventh consecutive Joint Commission accreditation, with this being its first evaluation under Medical Center standards. The excerpt says approximately 80% of surveyed locations offer primary care, which is now available at more than 65% of MinuteClinic locations.
Why it matters — The accreditation and primary-care availability figures provide information on the standards and scope of CVS Health’s MinuteClinic services.
A CVS Health unit will pay $315 million to resolve claims over allegedly illegal opioid prescriptions. The U.S. government alleged that CVS knowingly filled controlled-substance prescriptions that lacked a legitimate medical purpose, were invalid, or were not issued in the usual course of professional practice.
Why it matters — The resolution concerns allegations about CVS's handling of controlled-substance prescriptions and entails a $315 million payment by a company unit.
Zacks Investment Research discusses whether investors should rely on analyst recommendations when deciding whether to buy, sell, or hold CVS Health, noting that media reports about sell-side rating changes can influence a stock's price.
Why it matters — CVS watchers may find the discussion relevant when weighing analyst ratings and related coverage in their investment research.
The 27 Wall Street analysts covering CVS Health Corp. have a median 12-month price target of $113, with estimates ranging from $103 to $145. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 27 analysts covering CVS Health Corp., 25 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CVS Health Corp. 86 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, CVS Health Corp. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).
No one can know that. What the data says: the median 12-month target from 27 analysts implies +25.0% from the last close, and Ticker Nerd's factor model ranks CVS Health Corp. 86 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CVS Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $103 to $145 over the next 12 months.
CVS Health Corp. returned +17.0% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
CVS Health Corporation Common Stock represents ownership in CVS Health Corporation, a U.S. health solutions company headquartered in Woonsocket, Rhode Island.
The most recent item we track (Zacks Investment Research, 14 Oct 2026): "CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?". Zacks Investment Research compares CVS Health with Alignment Healthcare, saying CVS has stronger returns, rising earnings estimates and a lower valuation. It also says Aetna’s turnaround is gaining traction.
CVS Health Corporation Common Stock represents ownership in CVS Health Corporation, a U.S. health solutions company headquartered in Woonsocket, Rhode Island. The company operates across health care benefits, health services, pharmacy, and consumer wellness, serving members, patients, employers, health plans, and public-sector clients. Its businesses include health insurance and managed care services, pharmacy benefit management, retail and specialty pharmacy operations, and a broad range of consumer-facing health and wellness services. CVS Health also supports medication access, clinical care, and coordinated care delivery through integrated offerings that connect insurers, pharmacies, and care services. As a large diversified health care enterprise, CVS Health plays an important role in the U.S. health system by linking coverage, pharmacy services, and patient care in one integrated platform.
CEO Mr. J. David Joyner CEBS · 219,000 employees · United States · https://www.cvshealth.com
